Witzig 2005.

Methods	randomized controlled trial, placebo‐controlled
Participants	n = 344, lung, breast, other cancer (active incurable advanced stage); concomitant treatment: chemotherapy
Interventions	drug = Epoetin alpha dose = 40000 IU sc weekly hb‐target = 13‐15 g/dL planned ESA duration = 16 weeks
Outcomes	Primary: transfusion; secondary: Hb change, haemoglobin over time, predictors for response, incidence of nephrotoxicity, overall survival, tumor response, QoL
Notes	study number = 36512
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Low risk	computer generated
Allocation concealment?	Low risk	central randomization and coded drug packs of identical appearance